These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 6165708)

  • 1. Can historical controls be used in current clinical trials in osteosarcoma. Analysis of Prognostic factors.
    Broström LA; Aparisi T; Ingimarsson S; Lagergren C; Nilsonne U; Strander H; Söderberg G
    Int J Radiat Oncol Biol Phys; 1980 Dec; 6(12):1711-5. PubMed ID: 6165708
    [No Abstract]   [Full Text] [Related]  

  • 2. The interferons.
    S Afr Med J; 1980 Mar; 57(13):473-4. PubMed ID: 6154319
    [No Abstract]   [Full Text] [Related]  

  • 3. The role of interferons in the treatment of osteosarcoma.
    Whelan J; Patterson D; Perisoglou M; Bielack S; Marina N; Smeland S; Bernstein M
    Pediatr Blood Cancer; 2010 Mar; 54(3):350-4. PubMed ID: 19902521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant interferon treatment of human osteosarcoma.
    Strander H; Adamson U; Aparisi T; Broström LA; Cantell K; Einhorn S; Hall K; Ingimarsson S; Nilsonne U; Söderberg G
    Recent Results Cancer Res; 1978; 68():40-4. PubMed ID: 288109
    [No Abstract]   [Full Text] [Related]  

  • 5. Can historical controls be used in current clinical trials in osteosarcoma?. Metastases and survival in a historical and a concurrent group.
    Broström LA; Aparisi T; Ingimarsson S; Lagergren C; Nilsonne U; Strander H; Söderberg G
    Int J Radiat Oncol Biol Phys; 1980 Dec; 6(12):1717-21. PubMed ID: 6940855
    [No Abstract]   [Full Text] [Related]  

  • 6. [Interferon/Controlled study in 3-year survival of patients with osteosarcoma (author's transl)].
    Kotz R; Plattner E; Ramach W; Flener R; Bodo G
    Arzneimittelforschung; 1982; 32(4):446-8. PubMed ID: 6179524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II window studies: 10 years of experience and counting.
    Smith MA; Anderson B
    J Pediatr Hematol Oncol; 2001; 23(6):334-7. PubMed ID: 11563765
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment of osteosarcoma. The Scandinavian Sarcoma Group experience.
    Bruland ØS; Bauer H; Alvegaard T; Smeland S
    Cancer Treat Res; 2009; 152():309-18. PubMed ID: 20213398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging drugs for high-grade osteosarcoma.
    Hattinger CM; Pasello M; Ferrari S; Picci P; Serra M
    Expert Opin Emerg Drugs; 2010 Dec; 15(4):615-34. PubMed ID: 20690888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The outcomes and prognostic factors in patients with osteosarcoma according to age: a Japanese nationwide study with focusing on the age differences.
    Tsuda Y; Ogura K; Shinoda Y; Kobayashi H; Tanaka S; Kawai A
    BMC Cancer; 2018 May; 18(1):614. PubMed ID: 29855362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Chemotherapy of osteosarcomas].
    Kalifa C; Rubie H; Lemerle J
    Chir Pediatr; 1985; 26(4):233-7. PubMed ID: 3907873
    [No Abstract]   [Full Text] [Related]  

  • 12. Tumor size and prognosis in aggressively treated osteosarcoma.
    Bieling P; Rehan N; Winkler P; Helmke K; Maas R; Fuchs N; Bielack S; Heise U; Jurgens H; Treuner J; Romanowski R; Exner U; Kotz R; Winkler K
    J Clin Oncol; 1996 Mar; 14(3):848-58. PubMed ID: 8622033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols.
    Kager L; Zoubek A; Pötschger U; Kastner U; Flege S; Kempf-Bielack B; Branscheid D; Kotz R; Salzer-Kuntschik M; Winkelmann W; Jundt G; Kabisch H; Reichardt P; Jürgens H; Gadner H; Bielack SS;
    J Clin Oncol; 2003 May; 21(10):2011-8. PubMed ID: 12743156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bleomycin, cyclophosphamide, and dactinomycin in metastatic osteosarcoma: lack of tumor regression in previously treated patients.
    Pratt CB; Epelman S; Jaffe N
    Cancer Treat Rep; 1987 Apr; 71(4):421-3. PubMed ID: 2435408
    [No Abstract]   [Full Text] [Related]  

  • 15. High-dose methotrexate in osteogenic sarcoma: a 5-year experience.
    Jaffe N; Frei E; Watts H; Traggis D
    Cancer Treat Rep; 1978 Feb; 62(2):259-64. PubMed ID: 346215
    [No Abstract]   [Full Text] [Related]  

  • 16. Adjuvant chemotherapy of osteosarcoma: no runs, no hits, two men left on base.
    Holland JF
    J Clin Oncol; 1987 Jan; 5(1):4-6. PubMed ID: 3543237
    [No Abstract]   [Full Text] [Related]  

  • 17. Interferons: rationale for clinical trials in neoplastic disease.
    Borden EC
    Ann Intern Med; 1979 Sep; 91(3):472-9. PubMed ID: 382941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term adjuvant interferon treatment of human osteosarcoma. A pilot study.
    Strander H; Bauer HC; Brosjö O; Fernberg JO; Kreicbergs A; Nilsonne U; Silfverswärd C; Signomklao T; Söderlund V
    Acta Oncol; 1995; 34(6):877-80. PubMed ID: 7576758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Challenges in the management of bone tumors--1996.
    Craft AW
    Ann N Y Acad Sci; 1997 Sep; 824():167-79. PubMed ID: 9382441
    [No Abstract]   [Full Text] [Related]  

  • 20. Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: Learning From the Past to Move Forward.
    Lagmay JP; Krailo MD; Dang H; Kim A; Hawkins DS; Beaty O; Widemann BC; Zwerdling T; Bomgaars L; Langevin AM; Grier HE; Weigel B; Blaney SM; Gorlick R; Janeway KA
    J Clin Oncol; 2016 Sep; 34(25):3031-8. PubMed ID: 27400942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.